|
Post by surplusvalue on Aug 12, 2016 14:56:12 GMT -5
I see the insulin and outsulin and I see the warnings A note about warnings. Microwave frequencies are carcinogens. Do you see anyone not using a baby monitor or wifi? just sayin. toxicology report ec.europa.eu/health/ph_risk/committees/sct/documents/out128_en.pdf to find warnings on iPhone, settings, general, about, scroll down to legal. Legal notices, all the warnings are there. I want all the legal notices on the box top. These electrons..., the electric charge may.... I do not need a cell phone to live.
Never owned a microwave oven or used one. Studies indicated damage to DNA structure and the so called seals all leak. Cell phone radiation exposure is a nightmare waiting to unfold that very few want to talk about realistically. Its especially problematic in that its using an entire generation as guineau pigs. Dont get me started. Question though is why does almost the entire front face of the pamphlet have negative warnings with almost no positive references. Does the FDA require that this be the first thing consumers see? When drug commercials are aired the negative warnings come at the end. Just asking about placement.
|
|
|
Post by twibs66 on Aug 12, 2016 15:28:11 GMT -5
i like the characters insulin is sitting & outsulin is running -lol
|
|
|
Post by peppy on Aug 12, 2016 15:39:59 GMT -5
I see the insulin and outsulin and I see the warnings A note about warnings. Microwave frequencies are carcinogens. Do you see anyone not using a baby monitor or wifi? just sayin. toxicology report ec.europa.eu/health/ph_risk/committees/sct/documents/out128_en.pdf to find warnings on iPhone, settings, general, about, scroll down to legal. Legal notices, all the warnings are there. I want all the legal notices on the box top. These electrons..., the electric charge may.... I do not need a cell phone to live.
Never owned a microwave oven or used one. Studies indicated damage to DNA structure and the so called seals all leak. Cell phone radiation exposure is a nightmare waiting to unfold that very few want to talk about realistically. Its especially problematic in that its using an entire generation as guineau pigs. Dont get me started. Question though is why does almost the entire front face of the pamphlet have negative warnings with almost no positive references. Does the FDA require that this be the first thing consumers see?When drug commercials are aired the negative warnings come at the end. Just asking about placement. I believe so. www.afrezza.com/afrezza.pdf
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 12, 2016 19:35:22 GMT -5
i like the characters insulin is sitting & outsulin is running -lol I like the characters too. To me, it looks like the Afrezza Insulin robot-looking guy is meditating to "disappear" as quickly as possible to be able to "escape"—transforming itself into a "free" normal purple dude
|
|
|
Post by cm5 on Aug 12, 2016 22:34:24 GMT -5
Great post re: Outsulin ---
I'm laughing about Insulin meditating, trying to find a way to disappear!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 12, 2016 22:54:25 GMT -5
thats exactly the motto of the campaign- to make people talk
lets talk about meal time insulin and the outsulin component of it. ( highlights all the low sugar issues that people tweet/bitch about )
|
|
|
Post by buyitonsale on Aug 13, 2016 16:32:33 GMT -5
Below is my post from June 25th. I was very close or actually pretty right on... "The colors and name imply that this character is Afrezza specific, not a generic Technosphere reference. It feels to me that "to meet Outsulin" implies that it will be a supporting character for the marketing campaign, to indicate that it will work in tandem with Insulin in Afrezza to help it "Out" faster. Perhaps the running reference has to do with a relay scenario, where the Insulin does it's work first and then passes the baton to Outsulin... This is purely speculation of course but I think that leaving the body faster is the most important attribute of Afrezza that truly separates it from the rest. Therefore the "Out" effect is going to be the key emphasis within the DTC campaign." Read more: mnkd.proboards.com/thread/5758/outsulin-aimed-kids#ixzz4HFZR5YC7
|
|
|
Post by bioexec25 on Aug 13, 2016 17:10:50 GMT -5
Below is my post from June 25th. I was very close or actually pretty right on... "The colors and name imply that this character is Afrezza specific, not a generic Technosphere reference. It feels to me that "to meet Outsulin" implies that it will be a supporting character for the marketing campaign, to indicate that it will work in tandem with Insulin in Afrezza to help it "Out" faster. Perhaps the running reference has to do with a relay scenario, where the Insulin does it's work first and then passes the baton to Outsulin... This is purely speculation of course but I think that leaving the body faster is the most important attribute of Afrezza that truly separates it from the rest. Therefore the "Out" effect is going to be the key emphasis within the DTC campaign." Read more: mnkd.proboards.com/thread/5758/outsulin-aimed-kids#ixzz4HFZR5YC7I don't fully understand subliminal seduction in marketing (i'm a comp sci major) but it seems logical that relating OUT with diabetics who know the dangers of lingering or not sticking the landing (ok Olympics are on). If the population relates to the message it could really go viral. Afterall, the hand wringing of "does social media really matter" is simple, the majority of the time if anything real or true goes viral it is good imo. With the world being increasing controlled by a smaller and smaller number of people, OUTsiders transparency can only help shed some light on things. Biased maybe, but the internet is a weapon against the establishment, albeit the power is nearing an insurmountable level it seems.
|
|
Deleted
Deleted Member
Posts: 0
|
outsulin
Aug 13, 2016 19:33:04 GMT -5
via mobile
cm5 likes this
Post by Deleted on Aug 13, 2016 19:33:04 GMT -5
Go to google's search homepage. Look at the banner. The little orange guy bouncing around looks very similar to the purple Outsulin character.
|
|
|
Post by sayhey24 on Aug 13, 2016 21:18:02 GMT -5
Below is my post from June 25th. I was very close or actually pretty right on... "The colors and name imply that this character is Afrezza specific, not a generic Technosphere reference. It feels to me that "to meet Outsulin" implies that it will be a supporting character for the marketing campaign, to indicate that it will work in tandem with Insulin in Afrezza to help it "Out" faster. Perhaps the running reference has to do with a relay scenario, where the Insulin does it's work first and then passes the baton to Outsulin... This is purely speculation of course but I think that leaving the body faster is the most important attribute of Afrezza that truly separates it from the rest. Therefore the "Out" effect is going to be the key emphasis within the DTC campaign." Read more: mnkd.proboards.com/thread/5758/outsulin-aimed-kids#ixzz4HFZR5YC7I suspect that the label changes which MNKD will be submitting next month are directly related to this Outsulin marketing effort and that MNKD maybe trying to get a new insulin classification for afrezza - rapid exiting insulin - REI or maybe rapid out insulin - ROI. Al tried to get the FDA to classify afrezza as "ultra" rapid acting but could not get that label. I suspect the FDA will be hard pressed not to give them the rapid out insulin - ROI classification
|
|
|
Post by kc on Aug 13, 2016 21:31:52 GMT -5
Below is my post from June 25th. I was very close or actually pretty right on... "The colors and name imply that this character is Afrezza specific, not a generic Technosphere reference. It feels to me that "to meet Outsulin" implies that it will be a supporting character for the marketing campaign, to indicate that it will work in tandem with Insulin in Afrezza to help it "Out" faster. Perhaps the running reference has to do with a relay scenario, where the Insulin does it's work first and then passes the baton to Outsulin... This is purely speculation of course but I think that leaving the body faster is the most important attribute of Afrezza that truly separates it from the rest. Therefore the "Out" effect is going to be the key emphasis within the DTC campaign." Read more: mnkd.proboards.com/thread/5758/outsulin-aimed-kids#ixzz4HFZR5YC7I suspect that the label changes which MNKD will be submitting next month are directly related to this Outsulin marketing effort and that MNKD maybe trying to get a new insulin classification for afrezza - rapid exiting insulin - REI or maybe rapid out insulin - ROI. Al tried to get the FDA to classify afrezza as "ultra" rapid acting but could not get that label. I suspect the FDA will be hard pressed not to give them the rapid out insulin - ROI classification Seyhey glad to see you here. Rapid Acting labeling would be great. Al Knew it and stated that in a 2013 interview. Hope we see his dream and legacy achieve that designation soon. I have stated for 24 months that Afrezza will eventually be the GOLD STANDARD for diabetes treatment in the US and worldwide. I challenge Matt P. And Mike C. To achieve Al's dream.
|
|
|
Post by agedhippie on Aug 13, 2016 22:03:46 GMT -5
It may be that it's plausible to get a 'short acting' on the label which would also make it possible to sell as an adjunct treatment to both prandial insulin or non-insulin drugs. At this point I expect a lot of people to pile in saying that it is a prandial and why would you use anything else.
In the first instance the target market is endos and by making this an adjunct treatment that may allow them to prescribe it while remaining with the existing insulin, and also allow insurance to cover it in an adjunct role. Endo reads labels and this one is problematic - more DKA, no HbA1c improvement, cannot be used by current or recent smokers, or those with breathing issues, and has potential lung issues. With a list like that it's a hard sell. Now sold as an adjunct to treat spikes (much as mikep uses it) endos could justify it's use as an occasional correction (think rescue inhaler). This gets Afrezza prescribed and once that happens people will start to see it's advantages and use it more widely - endos see improved results and that patients are not dropping like flies with lung problems and the whole thing takes on a life of its own.
Of couse I could have had one drink to many (it's good for my blood sugar) but there are some random thoughts.
|
|
|
Post by rossomalley on Aug 14, 2016 0:35:00 GMT -5
Below is my post from June 25th. I was very close or actually pretty right on... "The colors and name imply that this character is Afrezza specific, not a generic Technosphere reference. It feels to me that "to meet Outsulin" implies that it will be a supporting character for the marketing campaign, to indicate that it will work in tandem with Insulin in Afrezza to help it "Out" faster. Perhaps the running reference has to do with a relay scenario, where the Insulin does it's work first and then passes the baton to Outsulin... This is purely speculation of course but I think that leaving the body faster is the most important attribute of Afrezza that truly separates it from the rest. Therefore the "Out" effect is going to be the key emphasis within the DTC campaign." Read more: mnkd.proboards.com/thread/5758/outsulin-aimed-kids#ixzz4HFZR5YC7I suspect that the label changes which MNKD will be submitting next month are directly related to this Outsulin marketing effort and that MNKD maybe trying to get a new insulin classification for afrezza - rapid exiting insulin - REI or maybe rapid out insulin - ROI. Al tried to get the FDA to classify afrezza as "ultra" rapid acting but could not get that label. I suspect the FDA will be hard pressed not to give them the rapid out insulin - ROI classification I would really like to see ROI from MNKD but am ok with REI for Afrezza.
|
|
|
Post by sayhey24 on Aug 15, 2016 18:46:01 GMT -5
I suspect that the label changes which MNKD will be submitting next month are directly related to this Outsulin marketing effort and that MNKD maybe trying to get a new insulin classification for afrezza - rapid exiting insulin - REI or maybe rapid out insulin - ROI. Al tried to get the FDA to classify afrezza as "ultra" rapid acting but could not get that label. I suspect the FDA will be hard pressed not to give them the rapid out insulin - ROI classification Seyhey glad to see you here. Rapid Acting labeling would be great. Al Knew it and stated that in a 2013 interview. Hope we see his dream and legacy achieve that designation soon. I have stated for 24 months that Afrezza will eventually be the GOLD STANDARD for diabetes treatment in the US and worldwide. I sure had hoped that it would have already become the Gold Standard - boy, was I wrong. I really thought by now the biggest issue would be manufacturing capacity and we are not even getting 300 scripts a week. I don't understand it. Now we have 70 sales dogs. You would think that if each one visited 5 endos a week they should be able to get at least 2 new scripts per endo per week. Assuming 2000 prescribing endo's if each one wrote 2 new scripts a week thats 4000. It make no sense to me. Even if afrezza was just an OK "inhaled" product each endo should be writing 1 script a week just for their patients who would rather inhale but afrezza is the greatest advancement in diabetes treatment in 90 years. Man, I just don't get it.
|
|
|
Post by agedhippie on Aug 16, 2016 8:38:33 GMT -5
Seyhey glad to see you here. Rapid Acting labeling would be great. Al Knew it and stated that in a 2013 interview. Hope we see his dream and legacy achieve that designation soon. I have stated for 24 months that Afrezza will eventually be the GOLD STANDARD for diabetes treatment in the US and worldwide. I sure had hoped that it would have already become the Gold Standard - boy, was I wrong. I really thought by now the biggest issue would be manufacturing capacity and we are not even getting 300 scripts a week. I don't understand it. Now we have 70 sales dogs. You would think that if each one visited 5 endos a week they should be able to get at least 2 new scripts per endo per week. Assuming 2000 prescribing endo's if each one wrote 2 new scripts a week thats 4000. It make no sense to me. Even if afrezza was just an OK "inhaled" product each endo should be writing 1 script a week just for their patients who would rather inhale but afrezza is the greatest advancement in diabetes treatment in 90 years. Man, I just don't get it. As a diabetic my insulin keeps me alive, if it screws up there is a good chance it's not a survivable experience for me and really fast. As a Type 1 that's somethink you live with every day. From and endo's standpoint it's the combination of non-inferiority and the black box warning. Why change someone onto a drug that has more side effects than the one they are on for no better result? The Endos are not going to believe salesmen but they are going to believe trial data, their own experience, and a few trusted colleagues. The best the sales force is going to achieve is to get an endo to agree to prescribe it for a couple of patients. The endo has to find someone who they knows is an early adopter, where they feels justified in changing the patients insulin, or asks (Sweedee's dad for example) then they are going to wait and see what happens. If all goes well they will add a few more people and wait. Rinse and repeat. Rome wasn't built in a day.
|
|